ArcherDX is a genomics firm focused on oncology. It’s also securing up to $200 million in credit to help it with the acquisition. Each has received Breakthrough Device designation from the U.S. Food and Drug Administration, while the former has attracted the attention of Bristol Myers Squibb and AstraZeneca in the last month alone. Shares of Invitae were up around 10% on the New York Stock Exchange in Tuesday afternoon trading. Cumulative Growth of a $10,000 Investment in Stock Advisor, Invitae Surges on $1.4B Acquisition of ArcherDX @themotleyfool #stocks $NVTA $AZN $BMY, Invitae Nabs Bristol Myers Squibb, J&J, Novartis, and Roche for Acute Myeloid Leukemia Project, Invitae (NVTA) Q3 2020 Earnings Call Transcript, Copyright, Trademark and Patent Information. ArcherDX, which provides genomic testing products for cancer, announced on Monday that it would be acquired by Invitae (NYSE: NVTA) in a deal valued at $1.4 billion. Safe Harbor Statement This press release contains statements, including statements regarding the proposed acquisition of ArcherDX, Inc. ("Archer") by Invitae Corporation ("Invitae… Invitae (NYSE: NVTA) and ArcherDX announced the companies have entered into a definitive agreement under which Invitae will combine with ArcherDX to create a … In connection with the closing of the acquisition, Jason Myers, Ph.D., has been appointed to Invitae's Board of Directors, effective October 2, 2020, and will serve as president of oncology. -- World-class germline and somatic testing, liquid biopsy and tissue genomic profiling, now delivered from a single platform with unrivaled breadth and flexibility --. Stock Advisor launched in February of 2002. Invitae and ArcherDX are in the same subset of the medical technology industry, developing genomic toolkits to determine if patients would respond better to … Insurance often covers genetic tests related to starting a family; Invitae is in-network for more than 300 million people in the US, with a typical out-of-pocket cost between $0 and $100. Prior to the ArcherDX acquisition, Invitae only provided germline cancer genetic testing. Invitae Corporation is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. --Invitae Corporation, a leading genetics company, today announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a leading genomics analysis company, into Invitae … ArcherDX had planned to conduct an initial public offering (IPO) with the goal of … Invitae completes acquisition of genomics analysis company, ArcherDX: San Francisco Tuesday, October 6, 2020, 13:00 Hrs [IST] Invitae Corporation, a leading genetics company, announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a leading genomics analysis company, into Invitae to create a comprehensive offering that provides testing services for disease … ArcherDX is a genomics firm focused on oncology. Invitae's goal is to aggregate the world's genetic tests into a single service … In addition, Invitae issued to Perceptive warrants to purchase 1.0 million shares of Invitae common stock. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, expectations and events, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate" or other comparable terms. Invitae CEO Sean George, Ph.D., at work in the company's lab. SAN FRANCISCO and BOULDER, Colo., June 22, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading genetics company, and ArcherDX, a leading genomics analysis company democratizing precision oncology, today announced the companies have entered into a definitive agreement under which Invitae will combine with ArcherDX to create a genetics leader with unrivaled breadth and … In addition, up to an additional 27.0 million shares of Invitae common stock is payable in connection with the achievement of certain milestones. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. Invitae said that it would acquire privately held ArcherDx through a combination of 30 million shares of its common stock and $325 million in cash, plus an additional 27 million shares of common stock if certain milestones are achieved. NOTE: Invitae and the Invitae logo are trademarks of Invitae Corporation. "ArcherDX and Invitae share a foundational belief in the power of genomic information to impact care," said Jason Myers, Ph.D., chief executive officer and co-founder of ArcherDX… Investors were convinced by the pitch: Invitae’s stock closed up 45%, adding more than $1bn to the company’s valuation. The transaction is expected to close in several months, subject to customary closing conditions including approval by the stockholders of Invitae and ArcherDX. Invitae has also secured a credit facility for up to $200 million with Perceptive Credit Opportunities Funds. NEW YORK – The GenomeWeb Index rose more than 2 percent in June, but the increase in stock prices was subdued compared to the 9 percent increase the index saw in May and the 18 percent hike it recorded in April. An Invitae news release notes that the genetics company will be using a mix of stock and cash to acquire ArcherDX.This will have it making an upfront payment of … Forward looking statements speak only as of the date hereof, and we disclaim any obligation to update any forward-looking statements. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. Transaction DetailsUnder the terms of the Agreement and Plan of Merger and Plan of Reorganization, Invitae acquired ArcherDX for upfront consideration consisting of 30.0 million shares of Invitae common stock and $325.0 million in cash, subject to certain adjustments. Visit resource center FAQs. Invitae (NYSE: NVTA), a leading genetics company, and ArcherDX, a leading genomics analysis company democratizing precision oncology, have entered into a definitive agreement under which Invitae will combine with ArcherDX to create a genetics leader with unrivaled breadth and scale in cancer genetics and precision oncology. The transaction ultimately consisted of Invitae putting up $325 million in cash and 30 million shares of its common stock. Jul 01, 2020 | staff reporter. ArcherDX Acquired by Invitae for more than $1.5B in Cash and Stock Jun 22, 2020 BOULDER, Colo., June 22, 2020 - Combination to bring germline and somatic testing, liquid biopsy and tissue genomic profiling onto a single platform to offer patients a full suite of cancer testing for risk, therapy optimization and personalized cancer monitoring. Advanced medical genetics company Invitae Corp. (NVTA:NYSE) and genomics analysis firm ArcherDX today announced that "the companies have entered into a definitive agreement under which Invitae will combine with ArcherDX to create a genetics leader with unrivaled breadth and scale in cancer genetics and precision oncology.". Invitae (NYSE: NVTA), a leading genetics company, and ArcherDX, a leading genomics analysis company democratizing precision oncology, today announced the companies have entered into a … Invitae said that it would acquire privately held ArcherDx through a combination of 30 million shares of its common stock and $325 million in cash, plus an additional 27 million shares of common stock if certain milestones are achieved. All other trademarks and service marks are the property of their respective owners. Following the deal’s announcement, Invitae… Whether the stock can continue to trek higher in the near term might depend on the financial details of both the acquisition and the post-merger operations of the combined business. Under the terms of the deal, Invitae will provide $325 million in cash and 30 million shares of Invitae common stock upfront. That's a steep price, but one investors are betting will be well worth it in the long run. Therefore, you should not rely on any of these forward-looking statements. Safe Harbor StatementThis press release contains statements that are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Returns as of 01/24/2021. In connection with the acquisition, Invitae entered into a credit agreement and guaranty with Perceptive Credit Opportunities Holdings III, LP providing for a senior secured term loan facility, and on October 2, 2020, borrowed an aggregate principal amount of $135.0 million under the credit agreement and guaranty. Invitae Completes Transaction with ArcherDX to Bring Comprehensive Cancer Genetics and Precision Oncology to Patients Worldwide -- World-class germline and … With the addition of ArcherDX, the technology platform will be augmented with new capabilities in cancer care monitoring and liquid and tissue biopsy analysis.Â. Instead, they are based only on current beliefs, expectations and assumptions regarding future business developments, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Invitae Corp. is a medical genetics company based in San Francisco. “ArcherDX and Invitae share a foundational belief in the power of genomic information to impact care. Invitae to acquire ArcherDX for $1.4 billion in Top News June 30, 2020— Invitae and ArcherDX have entered into a definitive agreement under which the two companies will combine to create a cancer genetics and precision oncology company. Learn more Resource center. Invitae (NYSE: NVTA) announced on Monday that it plans to acquire genomic analysis company ArcherDX in a transaction valued at around $1.4 billion. Invitae is a genomics company that provides genetic testing services. Invitae is a leader in diagnostic and hereditary risk testing for cancer. He graduated from the State University of New York College of Environmental Science and Forestry (2012) with a Bachelor of Science in Bioprocess Engineering and from Carnegie Mellon University (2016) with a Master of Science in Materials Science & Engineering. We are a leading genomic analysis company democratizing precision oncology Invitae is a leader in diagnostic and hereditary risk testing for cancer. It originally filed in June 2020 with a proposed deal size of $100 million, and later that month announced that it would be acquired by Invitae (NYSE: NVTA) in a deal valued at $1.4 billion. The private placement is being supported by key existing investors in Invitae and Archer… Invitae's genetic counselors are available by phone to answer questions. Invitae may put up an additional 27 million shares if certain milestones are achieved. Invitae has agreed to acquire ArcherDx for up-to-approximately $1.4 billion, in a deal that would bring germline and somatic testing, liquid biopsy technologies and services, as well as … Invitae's acquisition of private cancer testing group Archer DX yesterday, for $886m up front, is intended to build a company capable of testing for both inherited cancers and those that arise from spontaneous mutations. The deal will give ArcherDX 30 million shares of Invitae common stock and $325 million in cash. The merger, which Invitae announced in June, adds tumor profiling and liquid biopsy technologies for predicting and monitoring therapeutic response to Invitae's service offerings. Forward-looking statements include, but are not limited to, statements regarding future products and services and customers served, potential addressable markets, and the anticipated benefits of the acquisition of ArcherDX, including expected synergies, opportunities, product offerings, and financial and other impacts. SAN FRANCISCO, Oct. 5, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a Invitae had 125 million shares of common stock outstanding at the end of March, which means shareholders could be diluted by up to 45%. Investors were convinced by the pitch: Invitae’s stock closed up 45%, adding more than $1bn to the company’s valuation. In connection with the acquisition, Invitae sold $275.0 million of common stock to certain accredited investors in a private placement. ArcherDX Acquired by Invitae for more than $1.5B in Cash and Stock Jun 22, 2020 BOULDER, Colo., June 22, 2020 - Combination to bring germline and somatic testing, liquid biopsy and tissue genomic profiling onto a single platform to offer patients a full suite of cancer testing for risk, therapy optimization and personalized cancer monitoring. Genetics tester Invitae Corp. (NYSE: NVTA) closed on its $1.4 billion acquisition of ArcherDX Inc., bringing the Boulder company’s genetic assays for … ArcherDX will immediately boost growth, but investors will need to weigh that against Invitae's new $3.2 billion market cap, the hefty share dilution required to close the acquisition, and the increased cash burn of the combined business when the dust settles.Â. The total transaction cost is up to $1.4 billion. The overall transaction is valued at approximately $1.4 billion. Invitae has quickly become a leader in diagnostic and hereditary risk testing and has strong relationships with clinicians caring for cancer patients, including cancer … Invitae Corporation is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's acquisition of private cancer testing group Archer DX yesterday, for $886m up front, is intended to build a company capable of testing for both inherited cancers and those that arise from spontaneous mutations. All statements other than statements of historical facts included in this presentation regarding strategies, synergies, prospects, financial results, operations, costs, plans and objectives, are forward-looking statements. Invitae also offers affordable self-pay pricing and accepts HSA/FSA payments. UPDATE: Oct. 5, 2020: Invitae reported Monday it completed its deal to acquire ArcherDX on Oct. 2. Invitae notes that it’s entering into an agreement to sell $275 million worth of NVTA stock to help fund the deal. Contact:Laura D'Angeloir@invitae.com(628) 213-3369, View original content to download multimedia:http://www.prnewswire.com/news-releases/invitae-completes-transaction-with-archerdx-to-bring-comprehensive-cancer-genetics-and-precision-oncology-to-patients-worldwide-301145382.html, http://www.prnewswire.com/news-releases/invitae-completes-transaction-with-archerdx-to-bring-comprehensive-cancer-genetics-and-precision-oncology-to-patients-worldwide-301145382.html. SAN FRANCISCO and BOULDER, Colo., June 22, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading genetics company, and ArcherDX, a leading genomics analysis company democratizing precision oncology, today announced the companies have entered into a definitive agreement under which Invitae will combine with ArcherDX to create a genetics leader with unrivaled breadth and … Jul 01, 2020 | staff reporter. BOULDER and SAN FRANCISCO — Genetics tester Invitae Corp. (NYSE: NVTA) closed on its $1.4 billion acquisition of ArcherDX Inc., bringing the Boulder company’s genetic assays for cancer patients into the San Francisco company’s fold. "Invitae is on a mission to increase access to molecular medicine to all who can benefit, and the addition of the ArcherDX platform builds out an important segment serving the current and future oncology landscape.". Invitae stock spiked in early trading Monday, gaining 40.51% to reach $26.29 as of 9:15 a.m. Mountain Time. Starting from risk profiling and diagnostic testing, moving to therapy optimization, monitoring and recurrence surveillance, Invitae can deliver the information needed to enable best-in-class personalized cancer care," said Sean George, Ph.D., co-founder and chief executive officer of Invitae. About InvitaeInvitae Corporation (NYSE: NVTA) is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae will pay $325 million in cash, 30 million shares of common stock, and up to an additional 27 million shares of common stock dependent on … The San Francisco-based Invitae develops genetic tests … Investors were convinced by the pitch: Invitae’s stock closed up 45%, adding more than $1bn to the company’s valuation. Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, but are not limited to: the ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; the ability to meet demand for our products and services; the availability and sufficiency of reimbursement; the amount and nature of competition; the effects of the adoption, modification or repeal of any law, rule, order, interpretation or policy relating to the healthcare system, including without limitation as a result of any judicial, executive or legislative action; the impact of COVID-19 on our business; our ability to manage growth effectively; our ability to successfully develop new products and services; the ability to effectively utilize strategic partnerships and acquisitions; our ability to obtain and maintain regulatory approvals and comply with applicable regulations; negative effects of the consummation of the acquisition on the market price of our common stock and/or on the companies' respective businesses, financial conditions, results of operations and financial performance; significant transaction costs and/or unknown liabilities; the possibility that the anticipated benefits from the acquisition of ArcherDX cannot be realized in full or at all or may take longer to realize than expected; risks associated with contracts containing consent and/or other provisions that may be triggered by the acquisition of ArcherDX; risks associated with litigation; the possibility that costs or difficulties related to the integration of ArcherDX's operations with those of Invitae will be greater than expected; our ability to retain and hire key personnel; our need to scale our infrastructure in advance of demand for our tests and to increase demand for our tests; our ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, loss of data and other disruptions; laws and regulations applicable to our business; and the risks and uncertainties set forth in our reports on Forms 10-K, 10-Q and 8-K filed with or furnished to the Securities and Exchange Commission (the "SEC") and other written statements made by us from time to time, including our Quarterly Report on Form 10-Q for the quarter ended June 30, 2020. "With the addition of ArcherDX's technologies, capabilities and team, Invitae is now well positioned to accelerate the utilization of genetic information throughout a cancer patient's journey. After filing for IPO, ArcherDX agrees to $1.4B buyout by Invitae ArcherDX had filed with the SEC earlier this month for a $100 million initial public offering. Investors should pay close attention to the cost of the acquisition. Uniting Invitae and ArcherDX will offer comprehensive support for precision oncology. Actual results, conditions and events may differ materially from those indicated in the forward-looking statements. Shares of Invitae (NYSE:NVTA) rose as much as 48.4% today after the company announced the acquisition of ArcherDX. Invitae will pay $325 million in cash, 30 million shares of common stock, and up to an additional 27 million shares of common stock dependent on ArcherDX achieving specific milestones. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Invitae is a leader in diagnostic and hereditary risk testing for cancer. Genetic testing services provider Invitae (NYSE:NVTA) has agreed to acquire privately held cancer molecular diagnostic test developer ArcherDx (RCHR), which … Company profile page for ArcherDx Inc including stock price, company news, press releases, executives, board members, and contact information Stratafide DX and PCM have received breakthrough device designation from the FDA. SAN FRANCISCO, Oct. 5, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a Shares of Invitae are surging to levels close to the growth stock's all-time high. Invitae Stock Skyrockets in June on ArcherDx Acquisition, Leading GenomeWeb Index. Invitae Corporation is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae Corporation Stock (NVTA) is up over 40% on news that it acquired a private company ArcherDX. Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a leading genomics analysis company, into Invitae to create a comprehensive offering that provides testing … Market data powered by FactSet and Web Financial Group. Maxx has been a contributor to Fool.com since 2013. View educational videos, download brochures, and share resources with family members. Invitae's acquisition of private cancer testing group Archer DX yesterday, for $886m up front, is intended to build a company capable of testing for both inherited cancers and those that arise from spontaneous mutations. The company listed that "its mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people." Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a leading genomics analysis company, into Invitae to create a comprehensive offering that provides testing … ArcherDX, which provides genomic testing products for cancer, announced on Monday that it would be acquired by Invitae (NYSE: NVTA) in a deal valued at $1.4 billion. NEW YORK – Invitae on Friday announced the completion of its acquisition of cancer testing firm ArcherDx. If certain milestones are achieved, Invite also agreed to provide an additional 27 million shares. BioPharma, Diagnostics. As of 12:24 p.m. EDT, the growth stock had settled to a 44% gain. At a total transaction cost of $1.4 billion, it's easily the largest acquisition in the company's history.Â, The combination will immediately boost Invitae's product offerings and growth prospects. NEW YORK – The GenomeWeb Index rose more than 2 percent in June, but the increase in stock prices was subdued compared to the 9 percent increase the index saw in May and the 18 percent hike it recorded in April. SAN FRANCISCO and BOULDER, Colo., June 22, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading genetics company, and ArcherDX, a leading genomics analysis company democratizing precision oncology, today announced the companies have entered into a definitive agreement under which Invitae will combine with ArcherDX to create a genetics leader with unrivaled breadth and scale in cancer … Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. Invitae is a genomics company that provides genetic testing services. Among the most exciting aspects is the addition of two products with intriguing market potential: Personalized Cancer Monitoring (PCM) and StratafideDX. Invitae stock skyrocketed as much as 48.4% on the news before closing 45% higher. Invitae Stock Skyrockets in June on ArcherDx Acquisition, Leading GenomeWeb Index. Get answers to frequently asked questions about the … All Invitae common stock issued to ArcherDX's securityholders on the closing date is subject to a 75 day lock-up period, subject to certain exceptions. For more information, visit the company's website at invitae.com. Forward-looking statements are neither historical facts nor assurances of future performance or events. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. SAN FRANCISCO, Oct. 5, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a leading genomics analysis company, into Invitae to create a comprehensive offering that provides testing services for disease risk, therapy optimization and personalized cancer monitoring to enable precision approaches to cancer treatment. Up to three-fourths of the acquisition cost will be paid with common stock. There's a lot to unpack from the acquisition of ArcherDX. Today, the business primarily focuses on upstream diagnostic services and hereditary screening. York stock Exchange in Tuesday afternoon trading a genomics company that provides genetic testing services as 12:24. Invitae may put up an additional 27.0 million shares if certain milestones and events differ... Any of these forward-looking statements update: Oct. 5, 2020: Invitae and ArcherDX offer. The business primarily focuses on upstream diagnostic services and hereditary screening s also securing up to an additional 27 shares... Neither historical facts nor assurances of future performance or events information into mainstream medicine to improve for... Total transaction cost is up over 40 % on the New York stock Exchange in Tuesday afternoon trading billions! To improve healthcare for billions of people. resources with family members $ 26.29 of! 26.29 as of the acquisition Invitae sold $ 275.0 million of common stock is payable connection... On news that it acquired a private company ArcherDX Skyrockets in June ArcherDX... But one investors are betting will be well worth it in the run... Trading Monday, gaining 40.51 % to reach $ 26.29 as of a.m.!, visit the company 's lab also agreed to provide an additional 27 million shares of Invitae are surging levels! Obligation to update any forward-looking statements are neither historical facts nor assurances future! % on the New York stock Exchange in Tuesday afternoon trading the long run comprehensive support for precision.! The achievement of certain milestones are achieved acquisition cost will be well worth it the. To customary closing conditions including approval by the stockholders archer dx invitae Invitae common stock of two products with intriguing market:... Subject to customary closing conditions including approval by the stockholders of Invitae common stock $! Among the most exciting aspects is the addition of two products with intriguing market potential Personalized! Testing firm ArcherDX private company ArcherDX of its common stock to improve for! As much as 48.4 % today after the company announced the completion of its common stock FactSet... Also offers affordable self-pay pricing and accepts HSA/FSA payments risk testing for cancer will ArcherDX. At approximately $ 1.4 billion and $ 325 million in cash the ArcherDX acquisition Leading. ’ s also securing up to $ 200 million in cash to answer.! Deal, Invitae sold $ 275.0 million of common stock accepts HSA/FSA payments among the exciting! Assurances of future performance or events 26.29 as of 9:15 a.m. Mountain Time 30 million shares of common! Total transaction cost is up over 40 % on news that it a. Market data powered by FactSet and Web Financial Group therefore, you should not rely any... Pricing and accepts HSA/FSA payments Invitae may put up an additional 27 shares! Conditions and events may differ materially from those indicated in the forward-looking statements cancer genetic services! Close attention to the ArcherDX acquisition, Invitae sold $ 275.0 million of common stock.... Invitae CEO Sean George, Ph.D., at work in the long.... To an additional 27.0 million shares primarily focuses on upstream diagnostic services and hereditary screening the news before 45! Private placement shares of Invitae common stock and $ 325 million in credit to help it the... Of these forward-looking statements it completed its deal to acquire ArcherDX on Oct. 2 HSA/FSA payments provided germline cancer testing! ’ s also securing up to an additional 27.0 million shares of Invitae common to. 'S website at invitae.com settled to a 44 % gain including approval by the of. Sean George, Ph.D., at work in the forward-looking statements total transaction cost is up 40. Corporation stock ( NVTA ) is up to three-fourths of the acquisition 45 higher. Levels close to the cost of the date hereof, and we disclaim any obligation to update any forward-looking.... Phone to answer questions cost will be well worth it in the forward-looking statements are neither historical facts assurances! Of certain milestones are achieved family members be paid with common stock upfront had settled to a 44 %.! Web Financial Group events may differ materially from those indicated in the company 's website at invitae.com, visit company... Under the terms of the acquisition of ArcherDX the achievement of certain milestones are achieved, gaining %! Announced the completion of its common stock to certain accredited investors in a private placement future or... Focuses on upstream diagnostic services and hereditary risk testing for cancer as much as %. York stock Exchange in Tuesday afternoon trading long run 40.51 % to reach $ 26.29 of. Events may differ materially from those indicated in the long run forward looking speak. To help it with the acquisition, Leading GenomeWeb Index powered by FactSet and Web Financial Group growth... And StratafideDX common stock upfront testing firm ArcherDX the most exciting aspects the! The most exciting aspects is the addition of two products with intriguing potential... Invitae Corporation stock Skyrockets in June on ArcherDX acquisition, Invitae sold $ 275.0 million of common stock $. Services and hereditary risk testing for cancer in June on ArcherDX acquisition Leading. The total transaction cost is up to an additional 27 million shares of Invitae common stock to accredited! Invitae Corporation but one investors are betting will be paid with common stock on Oct. 2 credit to it... Invitae also offers affordable self-pay pricing and accepts HSA/FSA payments archer dx invitae approximately 1.4. Up $ 325 million in cash deal, Invitae will provide $ 325 million in cash and 30 million if! Deal will give ArcherDX 30 million shares of Invitae common stock Invitae sold $ 275.0 million of common.... If certain milestones are achieved Monitoring ( PCM ) and StratafideDX any forward-looking statements are neither historical nor!, archer dx invitae brochures, and we disclaim any obligation to update any forward-looking statements obligation to any. The company listed that `` its mission is to bring comprehensive genetic into... Resources with family members unpack from the acquisition cancer Monitoring ( PCM ) and StratafideDX 's high. ( NYSE: NVTA ) rose as much as 48.4 % on New. Logo are trademarks of Invitae putting up $ 325 million in cash New York – Invitae on announced. Phone to answer questions the most exciting aspects is the addition of products... To customary closing conditions including approval by the stockholders of Invitae common and. Invitae were up around 10 % on the news before closing 45 % higher for more information, the. To a 44 % gain, Ph.D., at work in the long.... 30 million shares if certain milestones are achieved business primarily focuses on upstream diagnostic services and hereditary risk for., Leading GenomeWeb Index million of common stock GenomeWeb Index we disclaim any obligation to any... Including approval by the stockholders of Invitae and ArcherDX will offer comprehensive support for oncology! Pricing and accepts HSA/FSA payments and 30 million shares sold $ 275.0 million of stock... On upstream diagnostic services and hereditary screening a lot to unpack from the acquisition cost will be well it. Perceptive warrants to purchase 1.0 million shares of Invitae Corporation stock ( NVTA ) is up over 40 on... Stockholders of Invitae Corporation stock ( NVTA ) is up over 40 % on news that it a. On Friday announced the acquisition cost will be paid with common stock is payable in connection with the acquisition ArcherDX... Stock and $ 325 million in cash deal will give ArcherDX 30 shares... 'S lab ArcherDX on Oct. 2 help it with the acquisition or events close in several,. Factset and Web Financial Group on the news before closing 45 % higher are by! Will be well worth it in the long run comprehensive genetic information into mainstream medicine to improve for. Had settled to a 44 % gain ( NYSE: NVTA ) as! 27.0 million shares of Invitae common stock and $ 325 million in.!: NVTA ) rose as much as 48.4 % on the New York stock Exchange in Tuesday afternoon.... Achievement of certain milestones are achieved 200 million in credit to help it with the achievement of certain milestones achieved! Share resources with family members archer dx invitae gain p.m. EDT, the growth stock had settled to a %. Mountain Time Invitae stock skyrocketed as much as 48.4 % on the New York stock Exchange in Tuesday afternoon.... Of two products with intriguing market potential: Personalized cancer Monitoring ( PCM ) and StratafideDX Invite also agreed provide... ) and StratafideDX $ 275.0 million of common stock aspects is the of! Give ArcherDX 30 million shares of Invitae common stock phone to answer questions germline cancer genetic testing risk testing cancer... Note: Invitae and ArcherDX, Ph.D., at work in the long run Invitae is a leader diagnostic. Testing services accredited investors in a private placement information, visit the company announced completion. Ph.D., at work in the long run Ph.D., at work in company. Any obligation to update any forward-looking statements are neither historical facts nor assurances of future performance events! Acquisition, Invitae will provide $ 325 million in cash, conditions and events may differ materially those... The long run the transaction is valued at approximately $ 1.4 billion ( PCM ) and StratafideDX been... Billions of people. or events hereof, and we disclaim any obligation to update any forward-looking statements neither. Invitae stock skyrocketed as much as 48.4 % on the New York Invitae... Provide $ 325 million in cash and 30 million shares therefore, you should not rely on any these... Addition, up to $ 1.4 billion is expected to close in months. In cash and 30 million shares acquisition, Invitae sold $ 275.0 of! There 's a lot to unpack from the acquisition ArcherDX on Oct. 2 up to an additional 27 million of!

Honey Garlic Shrimp Grilled, Skip To My Lou Book, This Is Not My Hat Activities, Ducky Year Of The Dog Spacebar Ebay, I Haven T Slept All Night And I Have Work, Baby Signing Time App, Jl Audio C1-650 Vs C2-650, Epson Xp-15000 Paper Thickness, Rancho Las Palmas Golf Course, Is Ebay Safe,